Background/Aims: Dyssynergic defecation (DD) accounts for 30-40% of patients with chronic constipation and is particularly prevalent in referral practices. Standard treatments (ST) including exercise, avoidance of constipating drugs, and increasing fluid & fiber intake often fail to improve symptoms. Laxatives provide inconsistent relief of constipation related symptoms, particularly in DD patients. Recent studies suggest that biofeedback (BF) therapy provides an effective treatment for DD patients. Aims: To conduct a systematic review and meta-analysis of randomized-controlled trials (RCTs) comparing BF therapy to standard treatments in DD patients. Methods: A search of MEDLINE, EMBASE, Google Scholar, Cochrane Central Register of Controlled Trials, ACP Journal Club, DARE, CMR, HTA, and abstracts from major GI meetings was performed. RCTs comparing the efficacy of BF vs. ST for weekly bowel movement (BM) frequency or global satisfaction in patients with DD were selected. Meta-analysis was performed using metan command in Strata 10.1. A funnel plot was created to assess for publication bias. The heterogeneity of the pooled estimate was tested with the inconsistency index (I2) statistic. Subgroup analyses (type of BF, duration of follow-up, study location, primary & secondary study outcomes, concurrent laxative use) were performed to account for any observed heterogeneity. Results: Systematic review identified >1000 citations. Upon detailed review, 7 treatment trials were identified of which 4 studies which randomized 241 patients with DD fulfilled our inclusion criteria and were included in the meta-analysis. Patients treated with BF reported an increase of 1.30 BM/ week, compared to 0.87 BM/week for patients treated with ST (WMD: 01.11, 95% CI: -0.99-3.20). Significant heterogeneity amongst studies was noted. Three studies reported data on patient satisfaction. The number of patients reporting satisfaction with therapy was higher in the BF group compared to the ST group (75.0% vs. 36.7%, RR: 2.15, 95% CI: 1.64-2.81, I2=81%). No other constipation-related outcomes were consistently reported amongst the included trials. Conclusions: These results suggest that BF therapy offers benefits for global satisfaction in patients with DD. Our analysis identified the need for further large, well designed clinical trials and the development of a common set of outcome measures which can be applied to randomized trials evaluating the efficacy of BF training for DD. Though stool frequency is commonly employed as the primary outcome measure in constipation trials, our results raise questions about whether this endpoint is the most appropriate primary outcome for trials evaluating BF for DD.